U.S. Markets closed

NewLink Genetics Corporation (NLNK)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.34-0.90 (-5.91%)
At close: 4:00PM EDT

14.48 0.14 (0.98%)
After hours: 4:22PM EDT

People also watch
TKMRCMRXSRPTCLVSPTCT
  • •Five of 6 (83%) evaluable patients treated with indoximod (600 mg or 1000 mg) achieved complete remission, with no evidence of minimal residual disease
  • I have just written a review looking into all the IDO inhibitors in clinical trials, especially comparing INCY with NLNK. I think that NLNK is currently undervalued. Have a look if you like:
    http://explicitpharma.com/2017/05/21/the-next-generation-of-immunotherapies-ido-inhibitors-continue-the-march-towards-approval/

  • May 11--WHO announced Democratic Republic of Congo Ebola outbreak, with one lab confirmed case of Ebola. 9 suspected cases currently. Outbreak reportedly in remote area of DRC.
  • profit taking day, tomorrow it will get green again!!!
  • Very strange reaction to what can only described as very positive interim data increasing the ORR from pembolizumab alone at 33% to 59% in the combination arm for the non-ocular melanoma and an even more impressive 52% if the ocular melanoma patients are included; no idea why that causes the shares to drop.
  • does it seem like Satnam is shorting the stock?
  • Found a great no fee daytrading newsletter, vist www.T0pm@rketgainers.c0m and sign up...so glad I did

  • NLNK had 60 patients with 59% RR while INCY had only 19 patients with 59% RR. NLNK had 200% more patient samples and for those in the biotech world, more samples matter more than fewer patients. Anyway, thanks for the cheap shares, bought at $16, $17.
  • Satan er Satnam is flooding the board with his 2" c uck
  • AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017 = 2000%++ UPSIDE POTENTIAL.... UNKNOWN LOW FLOAT GEM !!!

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a good sign .

    This undiscovered goldmine could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $85 Million
    Cash: $50.6 Million(cash runway into the first quarter of 2019.)
    Price:$3.70

    Shares Out: 23 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)

    Major Shareholders

    Herriott Tabuteau, MD 7 351 729 38,4%
    Fidelity Management & Research Co. 2 361 625 12,3%
    JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
    Mark Coleman, MD 647 998 3,38%
    BlackRock Fund Advisors 426 837 2,23%
    Stifel Trust Co., NA 415 279 2,17%
    The Vanguard Group, Inc. 272 189 1,42%
    Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
    JPMorgan Investment Management, Inc. 156 625 0,82%
    SSgA Funds Management, Inc. 134 688 0,70%

  • Results are positive, why the sell off?
  • Short for tomorrow crash now
  • Save my post, mark you calendar, this stock will be under $2 by April end
  • This Stock is Best Short in the world
  • Don't die slowly like a frog in warming water, jump out
  • My Cover is set at $2 GT60 days
  • I personally like stocktwits now and also the app stockstracker. Yahoo used to be the place to talk with some coffee or beer ... not anymore..
  • WHAT is the deal with Yahoo message board. such a lame place to trade views now. anyway gooooooooooo $NLNK
  • Is NLNK overvalued at current levels? Yo you should really check out awesome-STOCKS, they seem on point with their stocks.
  • Imageyourreactiongifs